Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple dosing study of intravenous Annexin A5 (ANXV) in moderate to severe COVID-19 pneumonia
2021-002200-12Phase 2Active
- Sponsor
- Maastricht University Medical Center+
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of annexin a5 in coronavirus pneumonia, sponsored by Maastricht University Medical Center+. Primary endpoints: Potential efficacy of intravenous ANXV and Safety and tolerability of intravenous ANXV. Started Dec 2021; status: active.
02
Drugs
annexin a5
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2021-002200-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002200-12.